title: Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of flexible-dose fesoterodine vs placebo in subjects with overactive bladder (OAB).
  
  
  METHODS
  In a 12-week double-blind trial, subjects were randomized to fesoterodine 4 mg or placebo once daily, taken within 4 hours of bedtime. At week 2, subjects could increase the fesoterodine dose to 8 mg (sham escalation for placebo). Subjects completed 3-day bladder diaries, Patient Perception of Bladder Condition, and Urgency Perception Scale at baseline and weeks 2, 6, and 12 as well as OAB Questionnaire at baseline and week 12.
  
  
  RESULTS
  Of 883 subjects, 63% and 73% of the fesoterodine (n = 438) and placebo (n = 445) groups, respectively, opted for dose escalation. Week 12 improvements from baseline in total micturitions, urgency episodes, urgency urinary incontinence episodes, frequency-urgency sum, and all OAB Questionnaire scales and domains, but not nocturnal micturitions or nocturnal urgency episodes, were significantly greater with fesoterodine than placebo (all P <.05). Treatment differences in micturitions and frequency-urgency sum were significant by week 2 and in urgency urinary incontinence and urgency episodes by week 6. Significantly greater percentages of subjects taking fesoterodine had improved Patient Perception of Bladder Condition and Urgency Perception Scale scores at weeks 2, 6, and 12 (P <.05). Dry mouth (fesoterodine, 26%; placebo, 8%) and constipation (fesoterodine, 11%; placebo, 6%) were the most common adverse events. In both groups, 87% of the subjects completed the trial; 8% and 5% of the fesoterodine and placebo groups, respectively, discontinued because of an adverse event.
  
  
  CONCLUSIONS
  Flexible-dose fesoterodine was efficacious and generally well tolerated for treatment of OAB symptoms.
authors.affiliation: Department of Urology, Vanderbilt University Medical Center, Room A 1302, Medical Center North, Nashville, TN 37232, USA. roger.dmochowski@vanderbilt.edu
authors.forename: Roger R
authors.initials: RR
authors.lastname: Dmochowski
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Peters
authors.forename: Jon D
authors.initials: JD
authors.lastname: Morrow
authors.forename: Zhonghong
authors.initials: Z
authors.lastname: Guan
authors.forename: Jason
authors.initials: J
authors.lastname: Gong
authors.forename: Franklin
authors.initials: F
authors.lastname: Sun
authors.forename: Paul
authors.initials: P
authors.lastname: Siami
authors.forename: David R
authors.initials: DR
authors.lastname: Staskin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D001559:Benzhydryl Compounds; C526675:fesoterodine